West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1

All NewsApril 23, 2026

West Pharmaceutical beats Q1 estimates on strong GLP-1 demand, raises 2026 outlook, and authorizes $1 billion buyback amid solid growth.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent